Market Research Logo

Lymphopenia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

Global Lymphopenia Therapeutics Market

About this market

Technavio’s lymphopenia therapeutics market analysis considers sales from acquired lymphopenia and inherited lymphopenia product segments. Our analysis also considers the sales of lymphopenia therapeutics in Asia, Europe, North America, and ROW. In 2018, the acquired lymphopenia segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising incidence of diseases from various therapy areas such as blood cancer and autoimmune disorders will play a significant role in the acquired lymphopenia segment to maintain its market position. Also, our global lymphopenia therapeutics market report looks at factors such as increasing risk factors for lymphopenia. However, adverse effects associated with therapeutics, high cost of therapeutics, and stringent regulations may hamper the growth of the lymphopenia therapeutics industry over the forecast period.

Global Lymphopenia Therapeutics Market

Overview

Increasing risk factors for lymphopenia

High prevalence of risk factors such as inherited diseases, autoimmune disorders, blood cancer or blood diseases, and infectious diseases such as AIDS has led to the reduction in lymphocyte counts in blood of a patient. This increases the incidence of lymphopenia. Pharmaceutical companies are investing in research and development activities to come up with effective and cost-efficient therapeutic drugs for lymphopenia. The availability of these drugs will lead to the expansion of the global lymphopenia therapeutics market at a CAGR of almost 4% during the forecast period.

Strategic alliances

Vendors are focusing on addressing the issues associated with high cost of research and development activities of therapeutic drugs by collaborating with pharmaceutical companies. They are also expanding their distribution networks by entering strategic alliances with other vendors. As a result, the development and commercialization of advanced therapies and drugs for lymphopenia is increasing. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global lymphopenia therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global lymphopenia therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lymphopenia therapeutics manufacturers, that include AbbVie Inc., Bristol-Myers Squibb Co., CSL Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Grifols SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, and Sanofi.

Also, the lymphopenia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Vendor: Key offerings
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Acquired lymphopenia - Market size and forecast 2018-2023
      • Table Acquired lymphopenia - Market size and forecast 2018-2023 ($ millions)
      • Table Acquired lymphopenia - Year-over-year growth 2019-2023 (%)
    • Inherited lymphopenia - Market size and forecast 2018-2023
      • Table Inherited lymphopenia - Market size and forecast 2018-2023 ($ millions)
      • Table Inherited lymphopenia - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision Framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Increasing research in regenerative medicines
    • Strategic alliances
    • Presence of patient assistance programs
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AbbVie Inc.
      • Table AbbVie Inc. - Vendor overview
      • Table AbbVie Inc. - Business segments
      • Table AbbVie Inc. - Organizational developments
      • Table AbbVie Inc. - Geographic focus
      • Table AbbVie Inc. - Key offerings
      • Table AbbVie Inc. - Key customers
    • Bristol-Myers Squibb Co.
      • Table Bristol-Myers Squibb Co. - Vendor overview
      • Table Bristol-Myers Squibb Co. - Business segments
      • Table Bristol-Myers Squibb Co. - Organizational developments
      • Table Bristol-Myers Squibb Co. - Geographic focus
      • Table Bristol-Myers Squibb Co. - Key offerings
      • Table Bristol-Myers Squibb Co. - Key customers
    • CSL Ltd.
      • Table CSL Ltd. - Vendor overview
      • Table CSL Ltd. - Business segments
      • Table CSL Ltd. - Organizational developments
      • Table CSL Ltd. - Geographic focus
      • Table CSL Ltd. - Segment focus
      • Table CSL Ltd. - Key offerings
      • Table CSL Ltd. - Key customers
    • Gilead Sciences Inc.
      • Table Gilead Sciences Inc. - Vendor overview
      • Table Gilead Sciences Inc. - Business segments
      • Table Gilead Sciences Inc. - Organizational developments
      • Table Gilead Sciences Inc. - Geographic focus
      • Table Gilead Sciences Inc. - Key offerings
      • Table Gilead Sciences Inc. - Key customers
    • GlaxoSmithKline Plc
      • Table GlaxoSmithKline Plc - Vendor overview
      • Table GlaxoSmithKline Plc - Business segments
      • Table GlaxoSmithKline Plc - Organizational developments
      • Table GlaxoSmithKline Plc - Geographic focus
      • Table GlaxoSmithKline Plc - Segment focus
      • Table GlaxoSmithKline Plc - Key offerings
      • Table GlaxoSmithKline Plc - Key customers
    • Grifols SA
      • Table Grifols SA - Vendor overview
      • Table Grifols SA - Business segments
      • Table Grifols SA - Organizational developments
      • Table Grifols SA - Geographic focus
      • Table Grifols SA - Segment focus
      • Table Grifols SA - Key offerings
      • Table Grifols SA - Key customers
    • Johnson & Johnson Services Inc.
      • Table Johnson & Johnson Services Inc. - Vendor overview
      • Table Johnson & Johnson Services Inc. - Business segments
      • Table Johnson & Johnson Services Inc. - Organizational developments
      • Table Johnson & Johnson Services Inc. - Geographic focus
      • Table Johnson & Johnson Services Inc. - Segment focus
      • Table Johnson & Johnson Services Inc. - Key offerings
      • Table Johnson & Johnson Services Inc. - Key customers
    • Merck & Co. Inc.
      • Table Merck & Co. Inc. - Vendor overview
      • Table Merck & Co. Inc. - Business segments
      • Table Merck & Co. Inc. - Organizational developments
      • Table Merck & Co. Inc. - Geographic focus
      • Table Merck & Co. Inc. - Segment focus
      • Table Merck & Co. Inc. - Key offerings
      • Table Merck & Co. Inc. - Key customers
    • Novartis AG
      • Table Novartis AG - Vendor overview
      • Table Novartis AG - Business segments
      • Table Novartis AG - Organizational developments
      • Table Novartis AG - Geographic focus
      • Table Novartis AG - Segment focus
      • Table Novartis AG - Key offerings
      • Table Novartis AG - Key customers
    • Sanofi
      • Table Sanofi - Vendor overview
      • Table Sanofi - Business segments
      • Table Sanofi - Organizational developments
      • Table Sanofi - Geographic focus
      • Table Sanofi - Segment focus
      • Table Sanofi - Key offerings
      • Table Sanofi - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook